Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Phase Study of the HS-10241 in Patients With Advanced Solid Tumors

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth.

melanoma
vomit
solid neoplasm
solid tumor
hysterectomy
  • 0 views
  • 05 Aug, 2020
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors

The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.

measurable disease
liver metastasis
carcinoma
solid tumour
cancer
  • 0 views
  • 05 Aug, 2020
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

psoriasis
cyp3a4 inhibitors
interstitial lung disease
thyroiditis
unstable angina
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation. APG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein and shows potent …

myeloid leukemia
cytarabine
hydroxyurea
acute myeloid leukemia
leukemia
  • 0 views
  • 16 Feb, 2024
  • 1 location
Expanded Access of Omidubicel for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

allogeneic transplantation
hematologic malignancy
investigational treatment
cancer
  • 0 views
  • 16 Feb, 2024
  • 4 locations
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2).

vegf
liver metastasis
postoperative complication
tyrosine
vascular endothelial growth factor
  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparative Effectiveness of Targeted Therapy in RA Patients

The objective of a multicenter prospective observational study is to compare effectiveness and safety of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with moderately to severely active rheumatoid arthritis patients who have had an inadequate response or intolerace to methotrexate.

tocilizumab
abatacept
disease modifying antirheumatic drugs
tofacitinib
rheumatism
  • 0 views
  • 16 Feb, 2024
  • 1 location
Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach

Metagenomic shotgun sequencing and bacterial messenger ribonucleic acid (mRNA) analysis will inform about metabolic potential and metabolic activity of the microbiota. Mass spectrometry will assess the small molecule content of stool and maternal milk samples. Network analysis will be used to assess the complex relationships between bacteria metabolic activities and …

placenta
microbiota
mass spectrometry
hypertension
  • 0 views
  • 16 Feb, 2024
  • 1 location